
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Click the title above for a link to open the Pharmaceutical Executive August 2023 issue in an interactive PDF format.
about 3 years ago
Executive Roundtable: Innovations in Global Pharma Labelingover 3 years ago
A Fierce Focus On Unmet Needover 3 years ago
Pharma's ESG Equation: Materiality and Strategy are Keyover 3 years ago
Bridging the Divide: Medical's Omnichannel Momentumover 3 years ago
AI and Drug 'Re-Innovation'over 3 years ago
More Evidence is Pointing to Potential Swing for Biotechover 3 years ago
2023 Proxy Season: Record Proposals, Sliding Supportover 3 years ago
Do Findings Point to a Tarnished COVID Victory for Europe?




